Skip to Content Facebook Feature Image

Synvo AI Raises US$1 Million to Give Enterprise AI a Memory

Business

Synvo AI Raises US$1 Million to Give Enterprise AI a Memory
Business

Business

Synvo AI Raises US$1 Million to Give Enterprise AI a Memory

2026-06-18 09:00 Last Updated At:09:15

NTU spinout secures seed investment from Fuel Ventures Asia; early deployment cuts a manufacturer's quotation generation workflow time from 45 minutes to under 5 minutes

SINGAPORE, June 18, 2026 /PRNewswire/ -- Enterprise AI has a memory problem. Every session starts blank—with no organisational context, no retained knowledge, and no accumulated understanding.

Synvo AI, a Singapore-based deep-tech company spun out of MMLab at Nanyang Technological University (NTU) with institutional support, is building the infrastructure to solve this challenge. Today, the company announced a US$1 million seed investment from Fuel Ventures Asia.

The funding will accelerate the commercialisation of Synvo AI's Enterprise Memory Layer, expand its engineering capabilities, and support enterprise AI deployments across Asia. Synvo AI's proprietary Enterprise Memory Layer powers AI systems and agents, enabling them to retain, retrieve, and reason across an organisation's documents, emails, video, audio, and business data. Designed for on-premises and on-device deployment, the technology enables enterprises to keep sensitive information within their own controlled environments while maintaining data privacy, security, governance, and sovereignty.

The business impact of giving AI a memory is already being demonstrated. A Singapore-based manufacturer reduced its quotation generation workflow time from 45 minutes to under 5 minutes using Synvo AI's technology. This single deployment reclaimed approximately 200 hours of sales capacity each month and generated an estimated SGD 120,000 in annual productivity savings.

Building on this momentum, the company is progressing multiple enterprise opportunities across Southeast Asia. Through its strategic partnership with Indonesia-based Sobat Bisnis Group (SBG), the technology arm of a billion-dollar family-owned business group, Synvo AI is expanding access to secure, privacy-first enterprise AI solutions in one of the region's fastest-growing markets.

"Today's AI can answer questions, generate content, and automate tasks, but it still lacks the organisational memory needed to learn, adapt, and build context the way experienced employees do. We are solving that problem. By giving AI an institutional memory, it accumulates value the longer a company uses it. Instead of treating every interaction as a new task, AI can build on organisational knowledge and provide more relevant, consistent, and useful outcomes over time. Our vision is to transform AI from a simple daily tool into a trusted enterprise asset that preserves and compounds organisational knowledge while maintaining full control over sensitive data."
Saim Yeong Harng | Co-Founder & CEO, Synvo AI

Commercialising research originating from MMLab at NTU Singapore, Synvo AI combines expertise in artificial intelligence, computer vision, memory systems, and enterprise software. This research foundation includes HippoCamp and FileGram, two complementary efforts in contextual agent memory. HippoCamp benchmarks whether AI agents can search, perceive, and reason across realistic multimodal personal file systems, where evidence is scattered across documents, emails, images, videos, audio, calendars, and other files. FileGram extends this direction from stored content to behavioural memory by grounding agent personalisation in file-system traces, including how users read, create, edit, organise, and revise files over time. Building on these ideas, Synvo AI's proprietary Lightweight Multimodal Memory (LiteMMem), the commercial architecture informed by FileGramOS, achieved the highest reported score on FileGramBench, a benchmark for evaluating memory-centric personalisation in file-system agents.

The founding team combines successful entrepreneurial experience, including a prior venture exit, with world-class AI research leadership and extensive experience commercialising advanced technologies. The company applies its proprietary technology to enterprise knowledge discovery, document intelligence, workflow automation, and AI-assisted decision support.

"As enterprises scale their use of AI, the conversation is rapidly shifting from basic capability to trust and context. Synvo AI has engineered a foundational solution to a major challenge in enterprise AI adoption— helping organisations securely capture, retain, and apply institutional knowledge, rather than simply automating isolated tasks. We believe a secure and deployable memory layer will become a foundational component of enterprise AI, and Synvo AI is well positioned to lead this category."
Jingjing Xu | Partner, Fuel Ventures; Managing Director, Fuel Ventures Asia

About Synvo AI

Synvo AI is a Singapore-based deep-tech company developing a proprietary Enterprise Memory Layer that powers AI systems and agents. Spun out of MMLab at Nanyang Technological University (NTU), the company builds privacy-first AI infrastructure that enables organisations to retain, retrieve, and reason across institutional knowledge while maintaining control over data sovereignty, security, and governance.

Synvo AI is a member of the NVIDIA Inception Program and HP Garage 2.0.

For more information, visit www.synvo.ai.

About Fuel Ventures Asia

Fuel Ventures Asia (FVA) is a Singapore-based venture capital platform established in 2023 by Fuel Ventures (UK), focused on bridging European technological innovation with Asia's industrial growth opportunities. The platform supports high-growth technology companies from Europe that have achieved market validation and are ready to scale across Asia. In recognition of its contribution to innovation and cross-border collaboration, FVA was awarded the "Most Influential British Company in Singapore" at the Singapore Annual Business Awards in October 2023. For more information, visit www.fuelventures.asia.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Synvo AI Raises US$1 Million to Give Enterprise AI a Memory

Synvo AI Raises US$1 Million to Give Enterprise AI a Memory

JENA, Germany, June 18, 2026 /PRNewswire/ -- ZEISS Medical Technology announced today that the company held a signing ceremony with the Aier Eye Hospital Group, entering into a strategic agreement for the purchase and installation of 25 ZEISS VISUMAX 800 femtosecond lasers across multiple Aier Eye Hospital locations. The signing ceremony was conducted on June 12 at the headquarters of Aier Eye Hospital Group in Changsha, Hunan Province.

The 25 ZEISS VISUMAX 800 systems covered by this agreement will be progressively deployed across Aier Eye Hospital's domestic and international networks starting later in 2026. The strategic partnership between ZEISS Medical Technology and Aier Eye Hospital Group aims to enhance high-quality patient care through technological innovation, helping to bring precise and well proven refractive surgery to patients worldwide.

"Aier Eye Hospital is one of ZEISS Medical Technology's most important global strategic partners. In the future, the two parties will explore deeper collaborative innovation in areas such as international expansion, integrated digital workflows and platforms, and AI-assisted diagnosis," said Martin Fischer, President & CEO of ZEISS Greater China.

"Our collaboration with ZEISS has long transcended mere equipment procurement. We are jointly exploring comprehensive synergies spanning from clinical management to digital applications. The introduction of 25 ZEISS VISUMAX 800 systems will help Aier further enhance surgical efficiency and patient satisfaction, aiming to set a new quality benchmark for refractive surgery worldwide," said Mr. Li LI, Co-Founder and Global President of Aier Eye Hospital Group.

Supporting a global patient care strategy

At the signing ceremony, ZEISS Medical Technology presented Aier Eye Hospital Group with a "Top Three" honorary plaque, acknowledging Aier's global leadership across three dimensions—equipment scale, talent pool, and clinical practice— further deepening its strategic partnership with ZEISS Medical Technology, including:

  1. Most ZEISS VISUMAX 800 Units Installed Globally: Aier Eye Hospital will be the ophthalmic institution with the largest installed base of ZEISS VISUMAX 800 systems worldwide;
  2. Most ZEISS SMILE pro-Certified Surgeons Globally: Aier Eye Hospital boasts the largest number of ZEISS SMILE pro-certified surgeons globally, demonstrating its strong advantages in technical training and talent development;
  3. Highest Number of Procedures with ZEISS SMILE pro in China: Aier Eye Hospital ranks first nationwide in the total number of KLEx procedures performed with ZEISS SMILE pro in China, maintaining a well-established position in clinical experience and patient satisfaction.

Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.

Company Profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units

ZEISS Medical Technology and Aier Eye Hospital Group Sign Strategic Agreement for 25 VISUMAX 800 Units

Recommended Articles